Background. We sought to identify the long-term renal survival rate and related risk factors of progression to renal failure in Chinese adult patients with IgA nephropathy (IgAN) and to quantify the effects of proteinuria during the follow-up on outcome in patients with IgAN. Methods. Patients with biopsy-proven primary IgAN in the Nanjing Glomerulonephritis Registry were studied. Renal survival and the relationships between clinical parameters and renal outcomes were assessed. Results. One thousand one hundred and fifty-five patients were enrolled in this study. The 10-, 15-and 20-year cumulative renal survival rates, calculated by Kaplan-Meier method, were 83, 74 and 64%, respectively. At the time of biopsy, proteinuria >1.0 g/day [hazard ratio (HR) 3.2, P < 0.001], estimated glomerular filtration rate (eGFR) <60 mL/ min/1.73m 2 (HR 2.6, P < 0.001), hypertension (HR 1.9, P < 0.001), hypoproteinemia (HR 2.0, P < 0.001) and hyperuricemia (HR 2.1, P < 0.001) were the independent risk factors. Multivariate Cox analysis showed the time-average proteinuria (TA-P) during follow-up was the most important risk factor of renal failure. Patients with TA-P >1.0 g/day were associated with a 9.4-fold risk than patients with TA-P <1.0 g/day (P < 0.001) and 46.5-fold risk than those with TA-P <0.5 g/day (P < 0.001). Moreover, patients who achieved TA-P <0.5 g/day benefit much more than those with TA-P between 0.5 and 1.0 g/day (HR 13.1, P < 0.001). Conclusions. Thirty-six percent of Chinese adult patients with IgAN progress to end stage renal disease within 20 years. Five clinical features-higher proteinuria, hypertension, impaired renal function, hypoproteinemia and hyperuricemia-are independent predictors of an unfavorable renal outcome. The basic goal of anti-proteinuric therapy for Chinese patients is to lower proteinuria <1.0 g/day and the optimal goal is to lower proteinuria to <0.5 g/day.
Introduction
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and is particularly prevalent in Asia. Our previous study showed that IgAN accounts for 45% of the primary glomerulonephritis in China [1] . IgAN have been presented in variable clinical and pathological patterns as well as different geographical prevalence, making it difficult to predict the risk of progression to end-stage renal failure in individuals. Long-term natural history studies in developed countries have demonstrated that the rate of progression has an extremely wide range, from 10 to 25% within 10 years and 25 to 50% within 20 years [2, 3] , and a number of studies have identified several risk factors associated with progression of IgAN [2] [3] [4] [5] [6] [7] [8] . However, long-term renal outcome and related risk factors for IgAN in large cohorts of Chinese patients remains unclear [7, 9] .
Proteinuria has been proved to be the most important predictor of renal failure in IgAN [5, 6, 10, 11] . However, the threshold above which the risk develops remains in debate. There is moderate quality evidence to suggest a favorable outcome when time-averaged proteinuria (TA-P) is reduced to <1.0 g/day [6] . Evidence remains lacking that the long-term renal outcomes differ between patients with a proteinuria at 0.5-1.0 g/day and those at <0.5 g/day.
We analyze herein the data from patients with biopsyproven primary IgAN in the Nanjing Glomerulonephritis Registry. The aim of the study is to identify the long-term renal survival and related risk factors of progression to renal failure in Chinese adult patients with IgAN. In addition, we examined the effects of sustained proteinuria during the follow-up on the outcome in this cohort of patients, in order to determine the optimal cutoff value of proteinuria for predicting an unfavorable outcome. We also assessed whether patients with a TA-P <0.5 g/day showed better improvement compared to those with proteinuria between 0.5 and 1.0 g/day.
Materials and methods
All patients with biopsy-proven primary IgAN in the Nanjing Glomerulonephritis Registry from 1989 to 2005 were reviewed. Patients who had a secondary cause of IgAN, such as systemic lupus erythematosus, HenochSchonlein purpura, chronic liver disease and other autoimmune disorders, were excluded. Patients who suffered from diabetes mellitus, acute interstitial nephritis and Alport's syndrome were excluded. Patients with biopsy aged <18 years or with follow-up <12 months were excluded. The baseline and follow-up data of the patients were obtained from the database of Nanjing Glomerulonephritis Registry. All follow-up data were updated to October 2010. The data included gender, age, family history of chronic renal failure or chronic glomerulonephritis, initial clinical manifestations, date of renal biopsy, systolic and diastolic blood pressure, 24-h urinary protein excretion, microscopic hematuria (measured as counts of erythrocytes per millimeter of urinary sediment in microscopic examination), presence of hypertension before renal biopsy (blood pressure >140/ 90 mmHg or requirement for anti-hypertensive therapy), serum creatinine, lipid, albumin and uric acid levels.
Estimated glomerular filtration rate (eGFR) was estimated using the four-variable Modification of Diet in Renal Disease (MDRD) formula. End-stage of renal disease (ESRD) was defined as eGFR <15 mL/min/ 1.73m 2 , initiation of dialysis or transplantation. The rate of renal function decline was expressed as the slope of eGFR, calculated by linear regression and the principal of least squares for each patient. Renal survival time was calculated from the biopsy to the last follow-up. Mean arterial pressure (MAP) was defined as diastolic pressure plus a third of the pulse pressure. For each patient, the summary measures (time-weighted averages) were calculated for proteinuria, blood pressure, MAP and microscopic hematuria from the area under the curve of serial measurements standardized by the length of the study [12] . The time-average MAP (TA-MAP) was defined as the ratio of the area under the curve of MAP during follow-up to the duration of the follow-up. The time-average blood pressure (TA-BP) was calculated with the same method as TA-MAP. Figure 1 shows serial measurements of proteinuria during follow-up in one of the patients in the current study. Similarly, for each patient, the TA-P represents the area under the curve of proteinuria during follow-up divided by the years of total follow-up. As the microscopic hematuria was severely skewed during the follow-up, logarithmic transformation was used to stabilize the variance of the microscopic hematuria. After log transformation of microscopic hematuria, we also calculated the time-average microscopic hematuria (TA-RBC) in a similarly way.
Normally distributed variables are expressed as mean AE SD. Non-parametric variables are expressed as median and range. Categorical variables are expressed in percentages. Renal survival was estimated with the Kaplan-Meier method. The relationship between parameters and renal survival was assessed using Cox regression, in which the outcome event was defined as a combined event: 50% reduction in renal function or ESRD. Receiver operating curve (ROC) of TA-P was drawn to determine the optimal cutoff predicting a combined event. All P-values were two-tailed and values <0.05 were considered statistically significant. Analyses were carried out using R (version 2.130) and SPSS (version 13; SPSS Inc., Chicago, IL).
Results

Demographic and clinical characteristics at biopsy
One thousand six hundred and thirteen patients with primary IgAN were recorded in the Nanjing Glomerulonephritis Registry from 1989 to 2005, of whom 458 cases were excluded, and 1155 cases were enrolled in this study. Among those patients excluded in this study, were 186 cases with follow-up <12 months, 245 cases <18 years old at biopsy, 49 cases with secondary IgAN and 22 cases with diabetes mellitus, acute interstitial nephritis or Alport's syndrome.
As described in Table 1 , most patients were young at the time of initial clinical presentation, with an equal proportion of men and women. The mean age at the time of initial clinical manifestations and renal biopsy were 31 AE 9 and 33 AE 9 years old, respectively. The intervals between initial onset of renal disease and the date of renal biopsy were severely skewed (median 11 months, interquartile range 3-37 months). The initial clinical manifestations of renal disease were by chance in a health check-up (19.5%), macroscopic hematuria (30%), edema (23.4%), hypertension (11.2%) and others (15.2%). About, 36% of patients had macroscopic hematuria before renal biopsy and 14% of cases had history of recurrent macroscopic hematuria. Thirty-one percent of patients had blood pressure >140/90 mmHg. About, 7% of patients had family history of kidney disease. The median of 24-h urinary protein excretion at biopsy was 0.89 g/day (interquartile range 0.51-1.59). About, 44% of the patients enrolled had proteinuria >1.0 g/day and 7% of cases had proteinuria >3.5 g/day. The mean levels of eGFR, creatinine, albumin, uric acid, total cholesterol and triglyceride were 89 AE 33 mL/ min/1. 
Clinical features during follow-up and outcomes of the cohort
As shown in Table 2 , during a median follow-up of 5.4 years (interquartile range, 4.1-7.2 years), 108 cases (9.4%) developed ESRD and 163 of cases (14.1%) achieved the combined event (50% decline in eGFR or ESRD). There were a total of 13 242 records in the database during the follow-up. However, the time point of visits was irregular and the median visits for each patient during the follow-up was 10 (interquartile range 6-16) times.
The 10-, 15-and 20-year cumulative renal survival rates after renal biopsy, calculated by Kaplan-Meier methods, were 83% [95% confidence interval (CI), 79-87%], 74% (95% CI, 67-81%) and 64% (95% CI, 54-77%), respectively ( Figure 2 ). The mean rate of renal function decline was À1.7 (interquartile range, À4.6 to 1.0) mL/min/ 1.73m 2 /year during the follow-up. While patients with eGFR <30 mL/min/1.73m 2 were excluded, the 10-, 15-and 20-year cumulative renal survival rates after renal biopsy, calculated by Kaplan-Meier methods, were 85% (95% CI, 81-89%), 76% (95% CI, 71-83%) and 67% (95% CI, 57-80%), respectively.
In light of severely skewed and uneven distributions of 24-h urinary protein excretion during the follow-up, the TA-P (see Materials and methods section) was used as the average level of follow-up proteinuria. The median of TA-P was 0.54 g/day (interquartile range 0.31-0.96 g/day). Patients with TA-P >1.0, 0.5-1.0 and <0.5 g/day, account for 23.8, 30.6 and 45.6%, respectively. In patients with initial proteinuria >1.0 g/day at biopsy, 43.3% of them had persistent proteinuria (TA-P >1.0 g/day), 37% of them had TA-P between 0.5 and 1.0 g/day and only 19.7% of them achieved TA-P <0.5 g/day during the follow-up.
The time-average systolic, diastolic blood pressure and MAP during follow-up were 126 AE 14, 79 AE 10 and 94 AE 11 mmHg, respectively. Nineteen percent of the enrolled patients received immunosuppressive therapy, consisting of variable dosages of corticosteroids with additional immunosuppressive agents and 90% of the patients had been treated with rennin-angiotensin system blockade for at least 12 months.
Risk factors at biopsy
At the time of biopsy, univariate analysis indicated that lower initial eGFR (eGFR <60 mL/min/1.73m 2 , HR 4.6, P < 0.001), hypertension at presentation (HR 4.0, P < 0.001), proteinuria (!1.0 g/day, HR 4.5, P < 0.001), hypoproteinemia (defined as serum albumin <35 g/L, HR 3.1, P < 0.001), hyperuricemia (defined as serum uric acid >430 lmmol/L, HR 3.5, P < 0.001), hypercholesterolemia (defined as serum total cholesterol >6 mmol/L, HR 1.6, P ¼ 0.02), hypertriglyceridemia (defined as serum triglyceride >2.2 mmo/L, HR 2.1, P < 0.001) and body mass index (BMI, HR 1.05, P ¼ 0.04) were associated with an increased risk for the combined event (Table 3) . There was no significant difference in the risk between patients with proteinuria <0.5 g/day and those with 0.5-1.0 g/day (HR 1.3, P ¼ 0.40). Patients with a history of gross hematuria had better renal outcomes than those without (HR 0.49, P < 0.001) and those with recurrent gross hematuria had even better renal outcomes than those without any gross hematuria (HR 0.29, P < 0.001).
These parameters significantly associated with outcome in univariate analysis were further considered in multivariate Cox regression model. It confirmed that, as shown in Table 3 , eGFR <60 mL/min/1.73m 2 (HR 2.6, P < 0.001), proteinuria >1.0 g/day (HR 3.2, P < 0.001), hypoproteinemia (HR 2.0, P < 0.001), hypertension at presentation (HR 1.9, P < 0.001) and hyperuricemia (HR 2.1, P < 0.001) were the independent predictors of renal outcome at the time of biopsy, whereas the associations with BMI, history of gross hematuria, hypercholesterolemia and hypertriglyceridemia failed to reach statistical significance.
Clinical parameters during follow-up
We also examined the effects of the clinical parameters during follow-up on the outcome in this cohort of patients. As shown in Table 4 , the TA-P, TA-RBC and TA-MAP were all associated with renal outcome in both univariate and multivariate Cox models.
As mentioned previously, TA-P was used to quantify the value of proteinuria during the follow-up in patients with IgAN, and ROC of TA-P was drawn to determine the optimal cutoffs predicting a worse outcome (ESRD or 50% reduction in eGFR). The area under the ROC (AUC) was 0.9 (data not shown), indicating the TA-P had high diagnostic accuracy for an unfavorable renal outcome. The optimal cutoff of TA-P was 0.97 g/day (sensitivity ¼ 83%, specificity ¼ 84%), which was approximated to 1.0 g/day to facilitate clinical practice, with slightly lower sensitivity (81%) and higher specificity (85%), indicating that the relationship between TA-P and renal outcome is dramatically altered down to levels as low as 1.0 g/day. As shown in Table 5 , the rate of renal function (eGFR) decline in patients with TA-P <1.0 g/day was À1.0 (interquartile range, À3.5 to 1.4) mL/min/ 1.73m 2 /year compared with À4.4 (interquartile range, À7.4 to À1.6) mL/min/1.73m 2 /year in those with TA-P >1.0 g/day. The cumulative renal survival from ESRD as well as from the combined events in patients with TA-P >1.0 g/day was greatly lower than those with TA-P >1.0 g/day. The univariate Cox analysis showed that patients with TA-P >1.0 g/day were associated with a 14-fold higher risk in renal survival from the combined events than those with TA-P <1.0 g/day (P < 0.001), and the multivariate Cox model (adjusted with TA-P, TA-MAP and initial eGFR at biopsy) showed patients with TA-P >1.0 g/day were associated with a 9.4-fold increased risk than those with TA-P <1.0 g/day (P < 0.001). These results suggest that the basic goal of antiproteinuric therapy during follow-up in patients with IgAN should be <1.0 g/day.
Moreover, patients with TA-P <0.5 g/day benefit more than those with TA-P between 0.5 and 1.0 g/day. The cumulative renal survival from ESRD as well as from the combined events in patients with TA-P 0.5-1.0 was also lower than those with TA-P <0.5 g/day ( Table 5) . The univariate Cox analysis showed patients with TA-P 0.5-1.0 g/day were associated with a 10.7-fold increased risk than those with TA-P <0.5 g/day (P < 0.001). In multivariate Cox analysis, patients with TA-P >1.0 g/day were associated with a 46.5-fold increased risk than those with TA-P <0.5 g/day (P < 0.001) and patients with TA-P <0.5 g/day could benefit more than those with TA-P 0.5-0.1.0 g/ day (HR 9.1, P < 0.001).
Patients who reached the same range of TA-P, regardless of their initial point of proteinuria, had a similar renal outcome. There are 347 patients with TA-P between 0.5 and 1.0 g/day, in which 47 patients had initial proteinuria <0.5 g/day (at biopsy), 115 patients had initial proteinuria between 0.5 and 1.0 g/day and 184 patients had initial proteinuria >1.0 g/day. The log-rank test showed no significant difference in cumulative renal survival rate from the combined events among the three groups (P ¼ 0.84). There are 516 patients with TA-P <0.5 g/day, in which 222 patients had initial proteinuria <0.5 g/day (at biopsy), 194 patients had initial proteinuria between 0.5 and 1.0 g/day and 98 patients had initial proteinuria >1.0 g/day. The logrank test also showed no significant difference in cumulative renal survival rate from the combined events among the three groups (P ¼ 0.42). There are 269 patients with TA-P >1.0 g/day, in which 13 patients had initial proteinuria <0.5 g/day (at biopsy), 40 patients had initial proteinuria between 0.5 and 1.0 g/day and 215 patients had initial proteinuria >1.0 g/day. The log-rank test also showed no significant difference in cumulative renal survival rate from the combined events among the three groups (P ¼ 0.13).
In addition to TA-P, TA-MAP and TA-RBC were also shown to be prognostic value of renal outcome (Table 4 ). Univariate analysis demonstrated that patients with TA-BP !130/80 mmHg were associated with an increased risk than those with TA-BP <130/80 mmHg (HR 2.5, P < 0.001, data not shown) and patients with higher TA-RBC were also shown to be associated with an increased risk of renal failure (HR 1.3, P ¼ 0.01). The multivariate analysis confirmed the similar significant associations.
Discussion
IgAN is the most common primary glomerulonephritis worldwide; however, the clinical outcome varies widely in patients from different ethnic groups [10] . In this study, we analyzed the clinical features and renal outcomes in a large unselected cohort of adult Chinese patients with primary IgAN. Our data shows that the 10-, 15-and 20-year cumulative renal survival rates from biopsy, calculated by Kaplan-Meier methods, were 83, 74 and 64%, respectively. At the time of renal biopsy, the impaired renal function, hypertension, higher level of proteinuria, hypoproteinemia and hyperuricemia were the independent risk factors of long-term renal survival. We used TA-P to represent the average level of proteinuria during follow-up and showed that TA-P was the strongest predictor of renal failure in patients with IgAN. The ROC of T-AP indicated the optimal cutoff for predicting an unfavorable renal outcome was~1.0 g/day. Multivariate Cox analysis showed that patients with TA-P >1.0 g/day were associated with a 9.4-fold increased risk of a combined event than those with TA-P <1.0 g/day. These results demonstrate that patients would have a more favorable outcome when TA-P is reduced to <1.0 g/day. Moreover, patients with TA-P <0.5 g/day were associated with a 9.1-fold increased risk than those with TA-P at 0.5-1.0 g/day, indicating that the optimal goal of anti-proteinuric therapy for Chinese patients with IgAN is <0.5 g/day.
Although numerous long-term renal survival analyses of patients with IgAN in developed countries have been published, few studies have calculated the long-term renal survival rate of Chinese patients. To the best of our knowledge, this is the first report to investigate the 20-year cumulative renal survival rate in a Chinese cohort. The 20-year renal survival rate after renal biopsy, in this cohort of patients, is 64%, which was slightly higher than the Japanese patients (61%) reported by Koyama et al. [11] , also higher than that of the miscellaneous patients from different continents (55%) reported by Geddes et al. [10] . The 10-year renal survival rate after renal biopsy (83%), in this cohort of patients, was similar with the cohorts from European, Japan, Hong Kong and Australian studies [2, 7] but higher than those in the studies from the USA (55-70%) and another Chinese cohort from Beijing (77%) [8, 9, 13] . It is a remarkable fact that latent IgA deposits are present in 16% of normal, healthy adults, living and cadaveric donors [14] . The variability in the renal outcome of IgAN in different studies may account Table 5 . Renal outcome based on categorical grouping of TA-P excretion during follow-up to some extent for the difference in the indications of kidney biopsy and health screening practice. Patients with selective biopsy indications would have lower renal survival rate. In this study, the indication of renal biopsy was relatively less selective, as suggested by the lower incidence of renal insufficiency (21.3%), proteinuria >1.0 g/day (43.4%) and hypertension (29.7%) at the time of biopsy. When patients with proteinuria <1.0 g/ day at biopsy were excluded in analysis, the 10-, 15-and 20-year cumulative renal survival rates from renal biopsy were 71, 63 and 54%, respectively (data not shown). It is also notable that patients with <12 months of follow-up were also excluded in this study, recognizing this was likely to exclude the most acute and rapidly progressive cases [15] . As most patients with IgAN are young at clinical presentation, and approximately one-third of patients with biopsy-proven IgAN will progress to ESRD within 20 years, it is important to identify those patients at risk. Proteinuria, especially proteinuria during follow-up, is the strongest independent predictive factor, which is confirmed by the present and other previous studies [2, 4, [6] [7] [8] [9] 13 ]. In contrast to other progressive glomerulonephritis, the concept of achieving 'partial remission' is not commonly associated with IgAN [6] and the threshold of the proteinuria above which the risk develops remains unclear. Reich et al. [6] demonstrated that the relationship between TA-P and renal outcome is dramatically altered down to the levels as low as 1 g/day. In our study, the ROC analysis also suggests the optimal threshold of TA-P for progression to renal failure is 1.0 g/day, with a sensitivity of 81% and specificity of 85%, and patients with TA-P !1.0 g/day are associated with a 10-fold higher risk than those with TA-P <1.0 g/day (P < 0.001). However, Reich et al. failed to achieve a different renal outcome in patients with TA-P <1 g/day. It remains unknown whether the long-term renal outcomes in patients with a proteinuria between 0.5 and 1.0 g/day differ from those with a proteinuria <0.5 g/day. In the present study, with multivariate Cox analysis, we firstly provide clear evidence that IgAN patients with TA-P <0.5 g/day benefit more than those with TA-P between 0.5 and 1.0 g/day (HR 9.1, P < 0.001). Moreover, patients who reached the same range of TA-P, regardless of their initial point of proteinuria, had a similar renal outcome. Therefore, we support the concept of achieving 'partial remission' proposed by Reich et al. [6] could be widely used in patients with IgAN; however, we believe that the optimal goal of anti-proteinuric therapy for patients with IgAN is <0.5 g/day.
Although the absence of a history of gross hematuria has been established as a 'risk factor' of patients with IgAN, the predictive value of the extent of microscopic hematuria, measured as count of urinary erythrocytes, remains uncertain. Some studies indicated it as an unfavorable risk factor, while others did not [3] . In addition, Goto et al. [5] showed that patients with mild hematuria, 1-29 red blood cells per high-power field (RBCs/HPF), had a higher risk of renal failure than those with severe hematuria !30 RBCs/HPF. The extent of microscopic hematuria is extremely variable from time to time in the same patient. We did not establish, in the current study, any association between the renal outcome and the extent of microscopic hematuria at the time of renal biopsy. The extent of microscopic hematuria during follow-up has not been explored in previous studies. Herein, we used TA-RBC to quantify it during the follow-up in patients with IgAN. As the microscopic hematuria was severely skewed during follow-up, logarithmic transformation was used to stabilize the variance of the microscopic hematuria. After log transformation of microscopic hematuria, we calculated the TA-RBC in a similar way of TA-P. We found that TA-RBC was associated with renal outcome. Multivariate Cox model showed that for every 10-fold increase in microscopic hematuria, risk for the combine event increased 210% (Table 4 , P < 0.001).
Our study also confirmed impaired renal function, hypertension, hypoproteinemia and hyperuricemia as independent prognostic factors conditioning the progression to renal failure [2, [16] [17] [18] . Other clinical parameters predicting outcome at the univariate analysis, i.e. the absence of history of gross hematuria, hyperlipoidemia and BMI, lost their prognostic value at the multivariate Cox analysis. Several studies indicated that gender and age at biopsy were also associated with the renal outcome in patients with IgAN [2] ; however, no such associations were shown in the current cohort of patients.
The limitations of this study must be recognized. A number of histological lesions have been reported to be of prognostic value [19] [20] [21] [22] [23] . Recently, a new classification for IgAN, the Oxford classification [15, 19] , proposed that four histopathological features (mesangial and endocapillary hypercellularity, segmental glomerulosclerosis and tubular atrophy/interstitial fibrosis) are predictive of renal outcome independent of clinical assessment. However, the classification must be validated in different cohorts. Here, the histological lesions were not analyzed, for we have launched a multicenter study for the validation of the Oxford Classification of IgAN in Chinese patients last September in Nanjing and the results will be published in the future. Moreover, this study is not a prospective therapeutic trial, and the therapeutic interventions in patients were miscellaneous. The study period is so long that the treatment strategy for patients is also changed over time. We did not evaluate the associations between the therapeutic interventions and renal outcomes in this cohort of patients. In addition, data of deaths were incomplete in this cohort of patients and the candidate factors which could be associated with death were not assessed in this study.
Conclusions
The cumulative renal survival was 83% within 10 years, 74% within 15 years and 64% within 20 years in this cohort of Chinese adult patients with IgAN. Five clinical features at the time of renal biopsy-proteinuria, hypertension, impairment of renal function, 'hypoproteinemia' and hyperuricemia are the independent predictors of an unfavorable outcome. Sustained proteinuria during the follow-up was the strongest predictor of renal failure. The suggested basic goal of anti-proteinuric therapy for Chinese patients is to lower proteinuria to 1.0 g/day and the optimal goal is to lower proteinuria to 0.5 g/day.
